Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
暂无分享,去创建一个
D. Centonze | G. Marfia | M. Filippi | C. Pozzilli | M. Rocca | G. Tedeschi | G. Comi | M. Trojano | P. Bramanti | E. Scarpini | L. Grimaldi | M. Buttmann | A. Ghezzi | R. Bergamaschi | F. Mattioli | R. Capra | P. Rieckmann | F. Patti | U. Nocentini | V. Morra | M. Amato | A. Uccelli | P. Gallo | A. Francia | E. Pietrolongo | S. Ruggieri | F. Bergh | A. Safavi | C. Chisari | F. Saccà | D. Maimone | M. Rottoli | V. Bianchi | F. Sangalli | M. Bartezaghi | M. Roscio | M. Danni | R. Turrini | Francesco Clara Grazia Girolama Alessandra Diego Vincenzo Br Patti Chisari Marfia Centonze Morra Cap | Diego Centonze | D. Centonze
[1] S. Ozakbas,et al. Effects of Fingolimod on Cognitive Status in Patients with Multiple Sclerosis: Prospective, Controlled Trial (P3.071) , 2016 .
[2] L. Kappos,et al. Fingolimod Effects on PASAT Score and Baseline Determinants of PASAT in a Large Cohort of RRMS Patients (P2.150) , 2016 .
[3] J. Bowen,et al. The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis , 2015, CNS Drugs.
[4] J. Fonseca. Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice , 2015, Neuroscience journal.
[5] P. Rieckmann,et al. Functional clinical outcomes in multiple sclerosis: Current status and future prospects. , 2015, Multiple sclerosis and related disorders.
[6] Massimo Filippi,et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis , 2015, The Lancet Neurology.
[7] Ludwig Kappos,et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis , 2015, Neurology.
[8] Hirofumi Ochi,et al. [Cognitive impairment in multiple sclerosis]. , 2014, Brain and nerve = Shinkei kenkyu no shinpo.
[9] Jeffrey A. Cohen,et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.
[10] P. Hämäläinen,et al. Neuropsychological rehabilitation for multiple sclerosis. , 2014, The Cochrane database of systematic reviews.
[11] H. Wiendl,et al. Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.
[12] J. DeLuca,et al. Treatment of cognitive impairment in multiple sclerosis: position paper , 2013, Journal of Neurology.
[13] F. Patti. Treatment of cognitive impairment in patients with multiple sclerosis , 2012, Expert opinion on investigational drugs.
[14] H. Hartung,et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) , 2012, Multiple sclerosis.
[15] M. Sá,et al. Cognitive Dysfunction in Multiple Sclerosis , 2012, Front. Neur..
[16] A. Giorgio,et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes , 2012, Neurology.
[17] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[18] Vicente Belloch,et al. Anatomical and functional differences between the Paced Auditory Serial Addition Test and the Symbol Digit Modalities Test , 2011, Journal of clinical and experimental neuropsychology.
[19] S. Rombouts,et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis , 2010, Neurology.
[20] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[21] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[22] M. Trojano,et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis , 2010, Multiple sclerosis.
[23] F. Paul,et al. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis , 2009, Neurology.
[24] Massimo Filippi,et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. , 2009, Archives of neurology.
[25] L. Pollak,et al. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. , 2007, The Israel Medical Association journal : IMAJ.
[26] R. Benedict,et al. Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis , 2007, Journal of clinical and experimental neuropsychology.
[27] Emilio Portaccio,et al. Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies , 2006, Journal of the Neurological Sciences.
[28] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[29] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[30] Edith Kaplan,et al. Reliability and validity of the Delis-Kaplan Executive Function System: An update , 2004, Journal of the International Neuropsychological Society.
[31] A. Achiron,et al. Effect of Interferon-beta-1b on Cognitive Functions in Multiple Sclerosis , 2002, European Neurology.
[32] J. Ruutiainen,et al. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. , 1997, Brain : a journal of neurology.
[33] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[34] F. Mattioli,et al. The Rao’s Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population , 2013, Neurological Sciences.
[35] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[36] A. Traboulsee,et al. The role of MRI in the diagnosis of multiple sclerosis. , 2006, Advances in neurology.
[37] J. Ridley. Studies of Interference in Serial Verbal Reactions , 2001 .
[38] Ethical principles for medical research involving human subjects. , 2001, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.
[39] Pharmaceutical Development. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE , 1998 .